Showing 681-690 of 1835 results for "".
- ASA Awards: Jon M. Hanifin, MD, Wins David Martin Carter Mentor Awardhttps://practicaldermatology.com/news/asa-awards-jon-m-hanifin-md-wins-david-martin-carter-mentor-award/2461728/The American Skin Association (ASA) announced the recipients of the 2023 David Martin Carter Mentor Award, 2023 George W. Hambrick Award, and the 2023 Research Achievement Awards at the International Societies for Investigative Dermatology (ISID) in Tokyo, Japan. <
- Skinvive by Juvéderm Scores FDA Nod to Improve Skin Smoothness in Cheekshttps://practicaldermatology.com/news/skinvive-by-juvederm-scores-fda-nod-to-improve-skin-smoothness-in-cheeks/2461717/The U.S. Food and Drug Administration gave its nod to Skinvive by Juvéderm to improve skin smoothness of the cheeks in adults over the age of 21. Skinvive by Juvéderm is the first and only hyaluronic acid (HA) intradermal microdroplet injection for skin smoothness availabl
- Rodan + Fields Gives Back: Company Joins The Recycling Partnershiphttps://practicaldermatology.com/news/rodan-fields-gives-back-company-joins-the-recycling-partnership/2461673/Rodan + Fields, LLC. is joining 80 leading companies to support The Recycling Partnership, a nonprofit organization committed to building a better recycling system. Investing in The Recycling Partnership will help strengthen recycling access, education and infrastructure, advance
- Dr. James G. Krueger Joins ASA’s Board of Directorshttps://practicaldermatology.com/news/dr-james-g-krueger-joins-asas-board-of-directors/2461651/James G. Krueger, MD, PhD, will join the American Skin Association’s (ASA) Board of Directors. Dr. Krueger is the David Martin Carter Professor in Clinical Investigation and Head of the Laboratory for Investigative Dermatology at The Rockefeller University in&
- New North Carolina Courage Jerseys to Feature Merz Aesthetics Sponsorshiphttps://practicaldermatology.com/news/new-north-carolina-courage-jerseys-to-feature-merz-aesthetics-sponsorship-1/2461632/Merz Aesthetics North America has launched its front-of-jersey sponsorship deal with the
- Dermatologist Terrence A. Cronin Jr., MD, Named New AAD Presidenthttps://practicaldermatology.com/news/dermatologist-terrence-a-cronin-jr-md-named-new-aad-president/2461615/Terrence A. Cronin Jr., MD, FAAD, is the new President of the American Academy of Dermatology. He will start his one-year term at the close of the Academy's Annual Meeting. Dr. Cronin will also hold the same position for the American Academy of Dermatology Association, a sister
- Phase 2 Data: Jeuveau “Extra-Strength” Dose Produces Lasting Resultshttps://practicaldermatology.com/news/phase-2-data-jeuveau-extra-strength-dose-produces-lasting-results/2461528/Evolus' Jeuveau Extra-Strength achieved one-point improvement on the Glabellar Lines Scale with the duration of effect lasting 26 weeks, representing a prolonged 6-month performance, the Company reports. The extra-strength glabellar line study is a multicenter, double
- La Roche Posay Celebrates Second Annual National HA Day on Jan. 21, 2023https://practicaldermatology.com/news/la-roche-posay-celebrates-second-annual-national-ha-day-on-jan-21-2023/2461510/La Roche-Posay is ringing in its second annual National Hyaluronic Acid Day on January 21st. To celebrate National Hyaluronic Acid Day, the brand is offering 20% off on orders of $65 or more on
- Allergan Aesthetics Rolls Out Juvéderm Volux XChttps://practicaldermatology.com/news/allergan-aesthetics-rolls-out-juvederm-volux-xc/2461507/Allergan Aesthetics' Juvéderm Volux XC is now available at aesthetic practices nationwide. The filler is approved for patients older than 21 with moderate to severe loss of jawline definition. "With 40% of aesthetically-aware consumers considering tre
- Journey Medical Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 for the Treatment of Papulopustular Rosaceahttps://practicaldermatology.com/news/journey-medical-completes-enrollment-in-phase-3-clinical-trials-evaluating-dfd-29-for-the-treatment-of-papulopustular-rosacea/2461506/Journey Medical Corp. announced that it has fully enrolled and randomized all of the patients in its Phase 3 clinical program to assess the safety, efficacy and tolerability of DFD-29 (minocycline modified release capsules 40 mg) for the treatment of papulopustular rosacea, the company announced